BIOMAT Database Logo BIOMAT Database Logo

Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. 1998

M A Pfeffer, and M Domanski, and Y Rosenberg, and J Verter, and N Geller, and P Albert, and J Hsia, and E Braunwald
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

The Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) trial is an 8,100 patient, randomized, double-blind, placebo-controlled trial designed to determine the usefulness of angiotensin-converting enzyme (ACE) inhibitors in treating coronary patients with preserved left ventricular ejection fraction. The hypothesis being tested in this trial is that patients with coronary disease and ejection fraction > or =40% who are treated with ACE inhibitors will experience a reduction in the incidence of cardiovascular death, nonfatal myocardial infarction, or a revascularization procedure compared with patients treated with conventional therapy. The design of the PEACE trial is described herein.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004452 Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Echocardiography, Contrast,Echocardiography, Cross-Sectional,Echocardiography, M-Mode,Echocardiography, Transthoracic,Echocardiography, Two-Dimensional,Transthoracic Echocardiography,2-D Echocardiography,2D Echocardiography,Contrast Echocardiography,Cross-Sectional Echocardiography,Echocardiography, 2-D,Echocardiography, 2D,M-Mode Echocardiography,Two-Dimensional Echocardiography,2 D Echocardiography,Cross Sectional Echocardiography,Echocardiography, 2 D,Echocardiography, Cross Sectional,Echocardiography, M Mode,Echocardiography, Two Dimensional,M Mode Echocardiography,Two Dimensional Echocardiography
D004656 Enalapril An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE. Enalapril Maleate,MK-421,MK421,Renitec,Renitek,MK 421,Maleate, Enalapril
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M A Pfeffer, and M Domanski, and Y Rosenberg, and J Verter, and N Geller, and P Albert, and J Hsia, and E Braunwald
New considerations relating to class effect with angiotensin-converting enzyme inhibitors--the PEACE study.
March 2005, Journal of clinical hypertension (Greenwich, Conn.),
M A Pfeffer, and M Domanski, and Y Rosenberg, and J Verter, and N Geller, and P Albert, and J Hsia, and E Braunwald
Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition.
September 2002, Rheumatology (Oxford, England),
M A Pfeffer, and M Domanski, and Y Rosenberg, and J Verter, and N Geller, and P Albert, and J Hsia, and E Braunwald
Angiotensin converting enzyme: substrate inhibition.
January 1989, Peptides,
M A Pfeffer, and M Domanski, and Y Rosenberg, and J Verter, and N Geller, and P Albert, and J Hsia, and E Braunwald
[Prevention with angiotensin-converting enzyme (ACE) inhibitors].
January 1992, Zeitschrift fur Kardiologie,
M A Pfeffer, and M Domanski, and Y Rosenberg, and J Verter, and N Geller, and P Albert, and J Hsia, and E Braunwald
Design of angiotensin converting enzyme inhibitors.
October 1999, Nature medicine,
M A Pfeffer, and M Domanski, and Y Rosenberg, and J Verter, and N Geller, and P Albert, and J Hsia, and E Braunwald
Cough associated with angiotensin converting enzyme inhibition.
January 1989, Journal of cardiovascular pharmacology,
M A Pfeffer, and M Domanski, and Y Rosenberg, and J Verter, and N Geller, and P Albert, and J Hsia, and E Braunwald
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).
March 2000, Journal of the American College of Cardiology,
M A Pfeffer, and M Domanski, and Y Rosenberg, and J Verter, and N Geller, and P Albert, and J Hsia, and E Braunwald
Angiotensin-converting enzyme inhibition, angiotensin, and cognition.
January 1992, Journal of cardiovascular pharmacology,
M A Pfeffer, and M Domanski, and Y Rosenberg, and J Verter, and N Geller, and P Albert, and J Hsia, and E Braunwald
Nephrotoxicity of angiotensin converting enzyme inhibition.
May 1987, Kidney international. Supplement,
M A Pfeffer, and M Domanski, and Y Rosenberg, and J Verter, and N Geller, and P Albert, and J Hsia, and E Braunwald
Angiotensin converting enzyme inhibition and renin inhibition.
April 1989, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
Copied contents to your clipboard!